Sector Expert: Charles Duncan

Piper Jaffray & Co.

Image: Charles Duncan

Dr. Charles Duncan is a managing director and senior research analyst at Piper Jaffray & Co. focusing on small- and mid-cap emerging growth biotechnology companies. Duncan brings more than 18 years of sellside experience and has been recognized by industry sources, including the StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis. He is a graduate of the University of Wisconsin and holds a doctorate in neuropharmacology from the University of Colorado.

Subscribe to
Streetwise Reports

Companies Commented On

  • Inovio Pharmaceuticals Inc.


Recent Interviews

With Potential Vaccines for Cancer, Ebola and Zika, Inovio Could Have an Explosive 2016 (5/18/16)
hypodermicvial630

Recent news from Inovio Pharmaceuticals Inc., a small-cap biotech developing immunotherapeutic vaccines that target cancer and infectious diseases like news-making viruses Ebola and Zika, has prompted Piper Jaffray analyst Charles Duncan to reiterate his thesis for investment in the company.

Piper Jaffray's Charles Duncan Addresses Pot Shots (6/26/14)

Early-stage biotech is a risky investment, but some bets are safer than others. Inovio Pharmaceuticals Inc. is doing high-stakes experimental work in both preventive and therapeutic medicine, addressing HIV, cancers and pre-cancers. The company's lead clinical program is in Phase 2 and a data readout is imminent, which has made the stock both volatile and an easy target for critics. In this interview with The Life Sciences Report, Senior Biotechnology Analyst and Managing Director Charles Duncan of Piper Jaffray & Co. addresses some of the criticisms that overhang the stock.

Charles Duncan: 2014 Is for Careful Stock Pickers, Not Dart Throwers (4/24/14)

Veteran Senior Biotechnology Analyst Charles Duncan of Piper Jaffray & Co. sees platform companies as the perfect way to play a consolidating market. We've had a big run in biotech, and Duncan believes now is the time to identify, through careful diligence, companies that can advance in a more temperate market. In this interview with The Life Sciences Report, Duncan discusses five biotech and specialty pharma innovators poised to produce therapies enabled by versatile and scalable technology platforms that target multiple disease indications.

Recent Quotes

"INO reported 2Q17 financial results, including $92M in cash prior to the recent $71M capital raise."

— Charles Duncan, Piper Jaffray & Co. (8/9/17)
more >

"We have recently performed additional diligence on INO's REVEAL and believe the program is well-designed to demonstrate clinically meaningful results which highlight potential advantages over surgery."

— Charles Duncan, Piper Jaffray & Co. (8/4/17)
more >

"INO announced the clinical hold has been lifted on its VGX-3100 cervical dysplasia program and it will now begin enrolling patients in the Phase III REVEAL studies."

— Charles Duncan, Piper Jaffray & Co. (6/8/17)
more >

"INO's 3112 can induce a T-cell response in a small group of HPV-associated H&N cancers."

— Charles Duncan, Piper Jaffray & Co. (5/18/17)
more >

"We see the main value-creating events as initiation of INO's Phase III in cervical dysplasia and data in HIV and Zika later this year."

— Charles Duncan, Piper Jaffray & Co. (5/11/17)
more >

"INO's revenues and R&D were slightly above our projections."

— Charles Duncan, Piper Jaffray & Co. (3/16/17)
more >

"Following today's updates we remain buyers of INO shares in anticipation of a smooth turn-around and 1H17 trial start for '3100, and upside from its Phase I Zika (4Q16) and Ebola (1H17) results."

— Charles Duncan, Piper Jaffray & Co. (11/9/16)
more >

"We believe INO's program can get back on track fairly quickly with a trial initiation as soon as 1H17."

— Charles Duncan, Piper Jaffray & Co. (10/24/16)
more >

more comments

"In advance of increasingly visible clinical progress expected across the platform over the next 12 months, we reiterate our Overweight rating for INO."

— Charles Duncan, Piper Jaffray & Co. (8/8/16)
more >

"INO is ahead of progress in oncology and infectious disease."

— Charles Duncan, Piper Jaffray & Co. (7/15/16)
more >

"In advance of INO's increasingly visible clinical execution in both immunotherapy and infectious diseases, we reiterate our Overweight rating."

— Charles Duncan, Piper Jaffray & Co. (5/9/16)
more >

"INO ended 2015 with $163M, sufficient to fund progress through 2017E."

— Charles Duncan, Piper Jaffray & Co. (3/14/16)
more >

"INO reported positive mouse data for its Zika vaccine."

— Charles Duncan, Piper Jaffray & Co. (2/19/16)
more >

"INO has received external validation on SynCon's flexibility and broad potential in infectious disease."

— Charles Duncan, Piper Jaffray & Co. (1/27/16)
more >

fewer comments


Due to permission requirements, not all quotes are shown.